Indivumed GmbH has announced the launch of the “Cancer Library Initiative”, an operation to further accelerate precision diagnostics and personalized treatment for cancer patients, in collaboration with A*STAR’s Institute of Molecular and Cell Biology (IMCB). Indivumed’s collaboration with IMCB builds on an agreement inked earlier this year between Indivumed and A*STAR’s Research Support Centre, to perform proteomic and phosphoproteomic analysis of tissue samples from Indivumed’s unique biobank.
Founded in 2002, Indivumed GmbH is a physician-led, International Organization for Standardization (ISO) certified, global oncology research company based in Hamburg, Germany. The company has established a world leading cancer database and biobank, retaining unique patterns of biomolecules such as RNA, DNA, and proteins as they existed in the human body.
The Agency for Science, Technology and Research (A*STAR) is Singapore’s top public-sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. A*STAR’s Institute of Molecular and Cell Biology (IMCB) has the vision of addressing the mechanistic basis of human diseases. A*STAR’s Research Support Centre (RSC) is a one-stop support centre for all biomedical R&D needs, now including more than 20 platforms.
According to the company, through this initiative, Indivumed and IMCB aim to build an Asian-centric Cancer Database (ACD) which leverages Singapore’s clinical network to achieve a truly integrated, comprehensive multiomic dataset containing rich clinical information of consenting patients. This data will be made available to scientists and clinicians in Singapore for academic and translational research.
The ACD will become an integral part of Indivumed’s global cancer database “IndivuType” and is the first-of-its-kind, integrating multi-omics data such as genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data together with extensive clinical information.
According to the company all data is derived from biospecimens collected under Indivumed’s stringent proprietary SOPs, which are recognized by professionals as being the gold standard for sample collection. The application of those standards for tissue collection and processing ensure the preservation of the biological reality of the tumor and therefore the reliability of the multi-omics analysis.
The ACD will be populated with comprehensive proteogenomic profiling data obtained from consenting patients. Cutting-edge analytical technology together with bioinformatic and artificial intelligence solutions integrated in a portal IT solution, provide highly reliable information for researchers and clinicians.
“Indivumed’s global access to biospecimens, as well as its professional standards for tissue collection, processing, and clinical data, provide unique opportunities to understand phenotypic effects in cancer patients,” … “We are pleased to forge a strong clinical research partnership with Indivumed in Singapore and participate in building this global multi-omics cancer database that contributes to better healthcare outcomes,” – Prof. Wanjin Hong, Executive Director of A*STAR’s IMCB
“We are delighted to partner with a global leader in personalised medicine who has the expertise to generate and analyse big molecular and clinical data from patients, and importantly also has established robust and scientifically-sound SOPs for tissue and clinical information collection. This collaboration enables us to unlock the wealth of tissue samples to obtain reliable, comprehensive data for the benefit of clinicians and researchers in Singapore.” – Prof. Soo Yong Tan, leading pathologist and Principal Investigator of the Cancer Library Initiative
“A*STAR’s IMCB in Singapore is one of the world’s leading research institutions, and Singapore represents a kind of “mini-Asia” adding important ethnical aspects to our global cancer database ʻIndivuTypeʼ. The outstanding scientific expertise and infrastructure of IMCB and the clinical expertise of Singapore clinics provide a unique opportunity to expand our global phenotypic cancer database, opening novel avenues and treatment modalities to fight this devastating malady.” – Prof. Hartmut Juhl, Founder and CEO of Indivumed